The present disclosure relates to recombinant nucleic acids and
gene therapy vectors comprising modified nucleic acids encoding aspartoacylase (ASPA), and variants thereof, for use in treating diseases and disorders associated with deficiency or dysfunction of ASPA, particularly Canavan
disease.